KUALA LUMPUR, Feb 3 -- Taconic Biosciences, a global leader in providing drug discovery animal model solutions has launched a new B2m-NOG mouse model, expanding its premier immuno-oncology portfolio.
The portfolio is built on the CIEA NOG mouse®, a severely immunodeficient mouse with diverse applications based on its improved ability to engraft human cells and tissues.
According to a statement, B2m-NOG significantly extends the study window after human peripheral blood mononuclear (PBMC) cell engraftment, providing more time to assess reactions to target drugs.
The extended study window dramatically expands immuno-oncology study types that can be run using the B2m-NOG model compared with more expensive and time-consuming options, such as hematopoietic stem cell-engrafted models.
Taconic also offers B2m-NOG mice pre-engrafted with human PBMCs.
Immuno-oncology leverages the body’s immune system to fight cancer, increasing the ability to target the disease.
Animal models used in this therapeutic development include special mice, which model human immune system function.
-- BERNAMA
No comments:
Post a Comment